# LTZ-232

Source: https://onco.cc/drugs/ltz-232/  
OnCo record `ltz-232` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LTZ-232 is an experimental bispecific antibody from LTZ Therapeutics, in phase 1 trials for metastatic colorectal cancer, other advanced solid tumours and malignant ascites.

## Summary

LTZ-232 is a bispecific antibody (myeloid cell engager) from LTZ Therapeutics. A first-in-class bispecific myeloid engager targeting EpCAM, built on the company's Universal Myeloid Cell Engager (U-MCE) platform. Its furthest stage is phase 1, for metastatic colorectal cancer, other advanced solid tumours and malignant ascites. ClinicalTrials.gov registers it in one study linked below. FDA IND cleared July 2026; first participant dosed in phase 1/1b, announced 29 October 2026 (NCT07878988). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: LTZ-232
- Modality: Bispecific antibody (myeloid cell engager)
- Mechanism: A first-in-class bispecific myeloid engager targeting EpCAM, built on the company's Universal Myeloid Cell Engager (U-MCE) platform.

## Sources

- LTZ Therapeutics: ltztherapeutics.com: https://www.ltztherapeutics.com/html/news/146.html
- LTZ Therapeutics: ltztherapeutics.com: https://www.ltztherapeutics.com/html/news/146.html
- LTZ Therapeutics: ltztherapeutics.com: https://www.ltztherapeutics.com/pipeline/index.html
- ClinicalTrials.gov: trials of LTZ-232: https://clinicaltrials.gov/search?intr=LTZ-232

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [EpCAM](https://onco.cc/targets/epcam/)
- companies: [LTZ Therapeutics](https://onco.cc/companies/ltz-therapeutics/)
- trials: [This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors](https://onco.cc/trials/nct07878988/)

---
JSON: https://onco.cc/api/v1/entities/ltz-232.json